Hospital Harm - Acute Kidney Injury
Compare Versions of: "Hospital Harm - Acute Kidney Injury"
The Compare function compares two years of the measure specifications found in the header of the measure's HTML. It does not include a comparison of any information in the body of the HTML, e.g., population criteria, Clinical Quality Language, or value sets.
Strikethrough text highlighted in red indicates information changed from the previous version. Text highlighted in green indicates information updated in the new eCQM version.
Compare 2025 version to
| Measure Information | 2025 Reporting Period | 2026 Reporting Period |
|---|---|---|
| Title | Hospital Harm - Acute Kidney Injury | Hospital Harm - Acute Kidney Injury |
| CMS eCQM ID | CMS832v2 | CMS832v3 |
| Short Name |
HH-AKI |
HH-AKI |
| CBE ID* | 3713e | 3713e |
| Measure Steward | Centers for Medicare & Medicaid Services (CMS) | Centers for Medicare & Medicaid Services (CMS) |
| Description | The measure assesses the number of inpatient hospitalizations for patients age 18 and older who have an acute kidney injury (stage 2 or greater) that occurred during the encounter. Acute kidney injury (AKI) stage 2 or greater is defined as a substantial increase in serum creatinine... value, or by the initiation of kidney dialysis (continuous renal replacement therapy (CRRT), hemodialysis or peritoneal dialysis). Show more >The measure assesses the number of inpatient hospitalizations for patients age 18 and older who have an acute kidney injury (stage 2 or greater) that occurred during the encounter. Acute kidney injury (AKI) stage 2 or greater is defined as a substantial increase in serum creatinine value, or by the initiation of kidney dialysis (continuous renal replacement therapy (CRRT), hemodialysis or peritoneal dialysis). Show less |
The measure assesses the number of inpatient hospitalizations for patients age 18 and older who have an acute kidney injury (AKI) stage 2 or greater that occurred during the encounter. AKI stage 2 or greater is defined as a substantial increase in serum creatinine value, or by the... initiation of kidney dialysis (continuous renal replacement therapy (CRRT), hemodialysis, or peritoneal dialysis). Show more >The measure assesses the number of inpatient hospitalizations for patients age 18 and older who have an acute kidney injury (AKI) stage 2 or greater that occurred during the encounter. AKI stage 2 or greater is defined as a substantial increase in serum creatinine value, or by the initiation of kidney dialysis (continuous renal replacement therapy (CRRT), hemodialysis, or peritoneal dialysis). Show less |
| Measure Scoring | Proportion measure | Proportion measure |
| Measure Type | Outcome | Outcome |
| Stratification |
None |
None |
| Risk Adjustment | Sex and Age. First vital signs since the encounter start:- Heart Rate- Respiratory Rate- Systolic Blood Pressure- Temperature.The estimated glomerular filtration rate (eGFR) which is calculated using the index serum creatinine, patient sex, and age-based formula.Patient sex collected for...risk adjustment and to calculate the eGFR is determined by the AdministrativeGender codes 'F' (female) and 'M' (male). These codes make up the "ONC Administrative Sex" value set and are also used to derive the supplemental data element of patient sex for the measure. All encounter diagnoses along with their present on admission (POA) indicators are being collected for the development of baseline risk adjustment model with initial focus on any encounter diagnoses captured for: - Cancer (leukemia, lymphoma, or metastatic cancer) - Diabetes - Heart failure - Hypertension - Obesity Encounter length of stay. Please see the Hospital Harm - Acute Kidney Injury Risk Adjustment Methodology Report on the eCQM-specific page on the eCQI Resource Center website: https://ecqi.healthit.gov/ Show more >Sex and Age. First vital signs since the encounter start: - Heart Rate - Respiratory Rate - Systolic Blood Pressure - Temperature. The estimated glomerular filtration rate (eGFR) which is calculated using the index serum creatinine, patient sex, and age-based formula. Patient sex collected for risk adjustment and to calculate the eGFR is determined by the AdministrativeGender codes 'F' (female) and 'M' (male). These codes make up the "ONC Administrative Sex" value set and are also used to derive the supplemental data element of patient sex for the measure. All encounter diagnoses along with their present on admission (POA) indicators are being collected for the development of baseline risk adjustment model with initial focus on any encounter diagnoses captured for: - Cancer (leukemia, lymphoma, or metastatic cancer) - Diabetes - Heart failure - Hypertension - Obesity Encounter length of stay. Please see the Hospital Harm - Acute Kidney Injury Risk Adjustment Methodology Report on the eCQM-specific page on the eCQI Resource Center website: https://ecqi.healthit.gov/ Show less |
Sex and Age First vital signs since the encounter start:- Heart Rate: {Beats}/min- Respiratory Rate: {Breaths}/min- Systolic Blood Pressure: mm[Hg]- Temperature: Cel [degF]The estimated glomerular filtration rate (eGFR) is calculated using the index serum creatinine, patient sex, and...age-based formula. Patient sex collected for risk adjustment and to calculate the eGFR is determined by the "Federal Administrative Sex" value set, which is also used to derive the supplemental data element of patient sex for the measure. All encounter diagnoses along with their present on admission (POA) indicators are being collected for the development of baseline risk adjustment model with initial focus on any encounter diagnoses captured for: - Cancer (leukemia, lymphoma, or metastatic cancer) - Diabetes - Heart failure - Hypertension - Obesity Encounter length of stay (days) Please see the Hospital Harm - Acute Kidney Injury Risk Adjustment Methodology Report on the eCQM-specific page on the eCQI Resource Center website: https://ecqi.healthit.gov/. Show more >Sex and Age First vital signs since the encounter start: - Heart Rate: {Beats}/min - Respiratory Rate: {Breaths}/min - Systolic Blood Pressure: mm[Hg] - Temperature: Cel [degF] The estimated glomerular filtration rate (eGFR) is calculated using the index serum creatinine, patient sex, and age-based formula. Patient sex collected for risk adjustment and to calculate the eGFR is determined by the "Federal Administrative Sex" value set, which is also used to derive the supplemental data element of patient sex for the measure. All encounter diagnoses along with their present on admission (POA) indicators are being collected for the development of baseline risk adjustment model with initial focus on any encounter diagnoses captured for: - Cancer (leukemia, lymphoma, or metastatic cancer) - Diabetes - Heart failure - Hypertension - Obesity Encounter length of stay (days) Please see the Hospital Harm - Acute Kidney Injury Risk Adjustment Methodology Report on the eCQM-specific page on the eCQI Resource Center website: https://ecqi.healthit.gov/. Show less |
| Rationale | This measure focuses on stage 2 or greater acute kidney injury as an outcome in the hospital inpatient setting. The incidence of AKI in general hospitalized patients is 10%–20%, and among critically ill patients, the incidence of AKI has been reported as high as 45–50%; in cardiac... surgery patients it ranges from 30%-50% (Thongprayoon et al., 2020). Less severe acute kidney injury and acute kidney injury requiring dialysis affect approximately 2,000 to 3,000 and 200 to 300 per million population per year, respectively. Acute kidney injury may result in the need for dialysis, and is associated with an increased risk of mortality (Schwager et al., 2023; Wilson et al., 2013). While not all instances of acute kidney injury are avoidable and may be due to natural progression of underlying illness or a complication of a necessary treatment such as chemotherapy, a proportion of acute kidney injury cases are preventable and treatable. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest careful management of hemodynamic status, fluids, and vasoactive medications for the prevention of acute kidney injury (KDIGO, 2012). Several studies identified through systematic literature searches developed or evaluated the effectiveness of acute kidney injury electronic alert systems (Schwager et al., 2023; Selby et al., 2012; Ahmed et al., 2015; Porter et al., 2014; Wilson et al., 2014; Kirkendall et al., 2014; Cho et al., 2012). These studies used data elements for defining acute kidney injury that were already present and populated in the electronic health record (EHR). For acute kidney injury diagnosis, all except two were limited to using serum creatinine levels, suggesting that this is the most reliable and consistently available electronic data element for defining acute kidney injury. Show more >This measure focuses on stage 2 or greater acute kidney injury as an outcome in the hospital inpatient setting. The incidence of AKI in general hospitalized patients is 10%–20%, and among critically ill patients, the incidence of AKI has been reported as high as 45–50%; in cardiac surgery patients it ranges from 30%-50% (Thongprayoon et al., 2020). Less severe acute kidney injury and acute kidney injury requiring dialysis affect approximately 2,000 to 3,000 and 200 to 300 per million population per year, respectively. Acute kidney injury may result in the need for dialysis, and is associated with an increased risk of mortality (Schwager et al., 2023; Wilson et al., 2013). While not all instances of acute kidney injury are avoidable and may be due to natural progression of underlying illness or a complication of a necessary treatment such as chemotherapy, a proportion of acute kidney injury cases are preventable and treatable. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest careful management of hemodynamic status, fluids, and vasoactive medications for the prevention of acute kidney injury (KDIGO, 2012). Several studies identified through systematic literature searches developed or evaluated the effectiveness of acute kidney injury electronic alert systems (Schwager et al., 2023; Selby et al., 2012; Ahmed et al., 2015; Porter et al., 2014; Wilson et al., 2014; Kirkendall et al., 2014; Cho et al., 2012). These studies used data elements for defining acute kidney injury that were already present and populated in the electronic health record (EHR). For acute kidney injury diagnosis, all except two were limited to using serum creatinine levels, suggesting that this is the most reliable and consistently available electronic data element for defining acute kidney injury. Show less |
This measure focuses on stage 2 or greater AKI as an outcome in the hospital inpatient setting. The incidence of AKI in general hospitalized patients is 10–20%, and among critically ill patients, the incidence of AKI has been reported as high as 45–50%; in cardiac surgery patients it... ranges from 30-50% (Thongprayoon et al., 2020). Less severe AKI and AKI requiring dialysis affect approximately 2,000 to 3,000 and 200 to 300 per million population per year, respectively. AKI may result in the need for dialysis and is associated with an increased risk of mortality (Schwager et al., 2023; Wilson et al., 2013). While not all instances of AKI are avoidable and may be due to natural progression of underlying illness or a complication of a necessary treatment such as chemotherapy, a proportion of AKI cases are preventable and treatable. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest careful management of hemodynamic status, fluids, and vasoactive medications for the prevention of AKI (KDIGO, 2012). Several studies identified through systematic literature searches developed or evaluated the effectiveness of AKI electronic alert systems (Schwager et al., 2023; Selby et al., 2012; Ahmed et al., 2015; Porter et al., 2014; Wilson et al., 2014; Kirkendall et al., 2014; Cho et al., 2012). These studies used data elements for defining AKI that were already present and populated in the electronic health record (EHR). For AKI diagnosis, all except two were limited to using serum creatinine levels, suggesting that this is the most reliable and consistently available electronic data element for defining AKI. Show more >This measure focuses on stage 2 or greater AKI as an outcome in the hospital inpatient setting. The incidence of AKI in general hospitalized patients is 10–20%, and among critically ill patients, the incidence of AKI has been reported as high as 45–50%; in cardiac surgery patients it ranges from 30-50% (Thongprayoon et al., 2020). Less severe AKI and AKI requiring dialysis affect approximately 2,000 to 3,000 and 200 to 300 per million population per year, respectively. AKI may result in the need for dialysis and is associated with an increased risk of mortality (Schwager et al., 2023; Wilson et al., 2013). While not all instances of AKI are avoidable and may be due to natural progression of underlying illness or a complication of a necessary treatment such as chemotherapy, a proportion of AKI cases are preventable and treatable. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest careful management of hemodynamic status, fluids, and vasoactive medications for the prevention of AKI (KDIGO, 2012). Several studies identified through systematic literature searches developed or evaluated the effectiveness of AKI electronic alert systems (Schwager et al., 2023; Selby et al., 2012; Ahmed et al., 2015; Porter et al., 2014; Wilson et al., 2014; Kirkendall et al., 2014; Cho et al., 2012). These studies used data elements for defining AKI that were already present and populated in the electronic health record (EHR). For AKI diagnosis, all except two were limited to using serum creatinine levels, suggesting that this is the most reliable and consistently available electronic data element for defining AKI. Show less |
| Clinical Recommendation Statement | Serum creatinine is an accepted proxy for acute kidney disease (Ostermann et al., 2020; KDIGO, 2012). It is cited by many guidelines for defining and monitoring acute kidney injury (Lameire et al., 2021; Ostermann et al., 2020; Lopes & Jorge, 2013; KDIGO, 2012). eGFR equations that... incorporate creatinine and cystatin C but omit race are more accurate and lead to smaller differences between Black participants and non-Black participants than new equations without race with either creatinine or cystatin C alone (Inker et al., 2021). As a result, a new race-neutral eGFR equation that that measures serum creatinine or cystatin C incorporate age, sex, and race to estimate measured GFR has been developed and is recommended by the Task Force from the National Kidney Foundation and American Society of Nephrology (Inker et al., 2021; Diao et al., 2021; Delgado et al., 2021; Delgado et al., 2022). It was recommended by the Task Force to use within the measure a Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation refit without the race variable. This functionality has been available to all laboratories in the United States (Delgado et al., 2021; Delgado et al., 2022), and has acceptable performance characteristics and potential consequences that do not disproportionately affect any one group of individuals. The KDIGO offers clinical practice guidelines for preventing and managing acute kidney injury: FLUIDS 3.1.1: In the absence of hemorrhagic shock, we suggest using isotonic crystalloids rather than colloids (albumin or starches) as initial management for expansion of intravascular volume in patients at risk for acute kidney injury or with acute kidney injury. (Level 2, grade B) VASOPRESSORS 3.1.2: We recommend the use of vasopressors in conjunction with fluids in patients with vasomotor shock with, or at risk for, acute kidney injury. (Level 1, grade C) PROTOCOLIZED HEMODYNAMIC MANAGEMENT 3.1.3: We suggest using protocol-based management of hemodynamic and oxygenation parameters to prevent development or worsening of acute kidney injury in high-risk patients in the perioperative setting (2C) or in patients with septic shock. (Level 2, grade C) In April 2019, KDIGO held a follow-up conference (Ostermann et al., 2020). The effectiveness of the 2012 KDIGO recommendations in preventing AKI was also noted to have been confirmed in small single-center randomized controlled trials (RCTs), such as the Prevention of AKI (PrevAKI) and the Biomarker Guided Intervention for Prevention of AKI (BigpAK) studies (Meersch et al., 2017; Göcze et al., 2018). In addition, results of RCTs have provided new data relevant to several facets of preventing and managing AKI, including early resuscitation, fluid therapy, prevention of contrast-associated AKI, and timing of acute renal replacement therapy (RRT) (Kellum et al., 2016; Nijssen et al., 2017; Self et al., 2018; Zarbock et al, 2016; Gaudry et al., 2016; Barbar et al., 2018). Show more >Serum creatinine is an accepted proxy for acute kidney disease (Ostermann et al., 2020; KDIGO, 2012). It is cited by many guidelines for defining and monitoring acute kidney injury (Lameire et al., 2021; Ostermann et al., 2020; Lopes & Jorge, 2013; KDIGO, 2012). eGFR equations that incorporate creatinine and cystatin C but omit race are more accurate and lead to smaller differences between Black participants and non-Black participants than new equations without race with either creatinine or cystatin C alone (Inker et al., 2021). As a result, a new race-neutral eGFR equation that that measures serum creatinine or cystatin C incorporate age, sex, and race to estimate measured GFR has been developed and is recommended by the Task Force from the National Kidney Foundation and American Society of Nephrology (Inker et al., 2021; Diao et al., 2021; Delgado et al., 2021; Delgado et al., 2022). It was recommended by the Task Force to use within the measure a Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation refit without the race variable. This functionality has been available to all laboratories in the United States (Delgado et al., 2021; Delgado et al., 2022), and has acceptable performance characteristics and potential consequences that do not disproportionately affect any one group of individuals. The KDIGO offers clinical practice guidelines for preventing and managing acute kidney injury: FLUIDS 3.1.1: In the absence of hemorrhagic shock, we suggest using isotonic crystalloids rather than colloids (albumin or starches) as initial management for expansion of intravascular volume in patients at risk for acute kidney injury or with acute kidney injury. (Level 2, grade B) VASOPRESSORS 3.1.2: We recommend the use of vasopressors in conjunction with fluids in patients with vasomotor shock with, or at risk for, acute kidney injury. (Level 1, grade C) PROTOCOLIZED HEMODYNAMIC MANAGEMENT 3.1.3: We suggest using protocol-based management of hemodynamic and oxygenation parameters to prevent development or worsening of acute kidney injury in high-risk patients in the perioperative setting (2C) or in patients with septic shock. (Level 2, grade C) In April 2019, KDIGO held a follow-up conference (Ostermann et al., 2020). The effectiveness of the 2012 KDIGO recommendations in preventing AKI was also noted to have been confirmed in small single-center randomized controlled trials (RCTs), such as the Prevention of AKI (PrevAKI) and the Biomarker Guided Intervention for Prevention of AKI (BigpAK) studies (Meersch et al., 2017; Göcze et al., 2018). In addition, results of RCTs have provided new data relevant to several facets of preventing and managing AKI, including early resuscitation, fluid therapy, prevention of contrast-associated AKI, and timing of acute renal replacement therapy (RRT) (Kellum et al., 2016; Nijssen et al., 2017; Self et al., 2018; Zarbock et al, 2016; Gaudry et al., 2016; Barbar et al., 2018). Show less |
Serum creatinine is an accepted proxy for AKI (Ostermann et al., 2020; KDIGO, 2012). It is cited by many guidelines for defining and monitoring AKI (Lameire et al., 2021; Ostermann et al., 2020; Lopes & Jorge, 2013; KDIGO, 2012). eGFR equations that incorporate creatinine and cystatin C... but omit race are more accurate and lead to smaller differences between Black participants and non-Black participants than new equations without race with either creatinine or cystatin C alone (Inker et al., 2021). As a result, a new race-neutral eGFR equation that measures serum creatinine or cystatin C incorporates age, sex, and race to estimate measured GFR has been developed and is recommended by the Task Force from the National Kidney Foundation and American Society of Nephrology (Inker et al., 2021; Diao et al., 2021; Delgado et al., 2021; Delgado et al., 2022). It was recommended by the Task Force to use within the measure a Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation refit without the race variable. This functionality has been available to all laboratories in the United States (Delgado et al., 2021; Delgado et al., 2022), and has acceptable performance characteristics and potential consequences that do not disproportionately affect any one group of individuals. The KDIGO offers clinical practice guidelines for preventing and managing AKI: FLUIDS 3.1.1: In the absence of hemorrhagic shock, we suggest using isotonic crystalloids rather than colloids (albumin or starches) as initial management for expansion of intravascular volume in patients at risk for acute kidney injury or with acute kidney injury. (Level 2, grade B) VASOPRESSORS 3.1.2: We recommend the use of vasopressors in conjunction with fluids in patients with vasomotor shock with, or at risk for, acute kidney injury. (Level 1, grade C) PROTOCOLIZED HEMODYNAMIC MANAGEMENT 3.1.3: We suggest using protocol-based management of hemodynamic and oxygenation parameters to prevent development or worsening of acute kidney injury in high-risk patients in the perioperative setting (2C) or in patients with septic shock. (Level 2, grade C) KDIGO held a follow-up conference in April of 2019 to review key relevant literature published since the 2012 KDIGO clinical practice recommendations (Ostermann et al., 2020). The effectiveness of the 2012 KDIGO recommendations in preventing AKI was also noted to have been confirmed in small single-center randomized controlled trials (RCTs), such as the Prevention of AKI (PrevAKI) and the Biomarker Guided Intervention for Prevention of AKI (BigpAK) studies (Meersch et al., 2017; Göcze et al., 2018). In addition, results of RCTs have provided new data relevant to several facets of preventing and managing AKI, including early resuscitation, fluid therapy, prevention of contrast-associated AKI, and timing of acute renal replacement therapy (RRT) (Kellum et al., 2016; Nijssen et al., 2017; Self et al., 2018; Zarbock et al, 2016; Gaudry et al., 2016; Barbar et al., 2018). Show more >Serum creatinine is an accepted proxy for AKI (Ostermann et al., 2020; KDIGO, 2012). It is cited by many guidelines for defining and monitoring AKI (Lameire et al., 2021; Ostermann et al., 2020; Lopes & Jorge, 2013; KDIGO, 2012). eGFR equations that incorporate creatinine and cystatin C but omit race are more accurate and lead to smaller differences between Black participants and non-Black participants than new equations without race with either creatinine or cystatin C alone (Inker et al., 2021). As a result, a new race-neutral eGFR equation that measures serum creatinine or cystatin C incorporates age, sex, and race to estimate measured GFR has been developed and is recommended by the Task Force from the National Kidney Foundation and American Society of Nephrology (Inker et al., 2021; Diao et al., 2021; Delgado et al., 2021; Delgado et al., 2022). It was recommended by the Task Force to use within the measure a Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation refit without the race variable. This functionality has been available to all laboratories in the United States (Delgado et al., 2021; Delgado et al., 2022), and has acceptable performance characteristics and potential consequences that do not disproportionately affect any one group of individuals. The KDIGO offers clinical practice guidelines for preventing and managing AKI: FLUIDS 3.1.1: In the absence of hemorrhagic shock, we suggest using isotonic crystalloids rather than colloids (albumin or starches) as initial management for expansion of intravascular volume in patients at risk for acute kidney injury or with acute kidney injury. (Level 2, grade B) VASOPRESSORS 3.1.2: We recommend the use of vasopressors in conjunction with fluids in patients with vasomotor shock with, or at risk for, acute kidney injury. (Level 1, grade C) PROTOCOLIZED HEMODYNAMIC MANAGEMENT 3.1.3: We suggest using protocol-based management of hemodynamic and oxygenation parameters to prevent development or worsening of acute kidney injury in high-risk patients in the perioperative setting (2C) or in patients with septic shock. (Level 2, grade C) KDIGO held a follow-up conference in April of 2019 to review key relevant literature published since the 2012 KDIGO clinical practice recommendations (Ostermann et al., 2020). The effectiveness of the 2012 KDIGO recommendations in preventing AKI was also noted to have been confirmed in small single-center randomized controlled trials (RCTs), such as the Prevention of AKI (PrevAKI) and the Biomarker Guided Intervention for Prevention of AKI (BigpAK) studies (Meersch et al., 2017; Göcze et al., 2018). In addition, results of RCTs have provided new data relevant to several facets of preventing and managing AKI, including early resuscitation, fluid therapy, prevention of contrast-associated AKI, and timing of acute renal replacement therapy (RRT) (Kellum et al., 2016; Nijssen et al., 2017; Self et al., 2018; Zarbock et al, 2016; Gaudry et al., 2016; Barbar et al., 2018). Show less |
| Improvement Notation |
A lower measure score indicates higher quality |
Decreased score indicates improvement |
| Definition | Inpatient hospitalizations: Includes time in the emergency department and observation when the transition between these encounters (if they exist) and the inpatient encounter are within an hour or less of each other. The numerator harm, AKI (stage 2 or greater), is defined as a...substantial increase in serum creatinine value during the encounter, as evidenced by a subsequent increase in value at least 2 times higher than the lowest serum creatinine value, and the increased value is greater than the highest sex-specific normal value for serum creatinine. The following steps are performed to determine if this criterion for AKI is met: - To identify AKI, evaluate if any serum creatinine value obtained between 48 hours after the start of the encounter and either 30 days after the start of the encounter or discharge, whichever is sooner, is at least 1.5 times higher than the lowest value obtained within the prior 7 days. If yes, then: - Evaluate if the increased serum creatinine is greater than the highest sex-specific normal value for serum creatinine. If yes, then: - To stage AKI, evaluate if any serum creatinine value obtained between 48 hours after the start of the encounter and either 30 days after the start of the encounter or discharge, whichever is sooner, is at least 2 times higher than the lowest prior value (at any prior time) during that encounter. If yes, then: - Evaluate if the increased serum creatinine value is greater than the highest sex-specific normal value for serum creatinine. If yes, then a harm (AKI stage 2 or greater) has been identified. The highest normal serum creatinine value for females is defined as 1.02 mg/dL. The highest normal serum creatinine value for males is defined as 1.18 mg/dL. The eGFR values are calculated using the CKD-EPI Creatinine Equation, recommended by the National Kidney Foundation (Delgado et al., 2022). This is a sex-specific, race-neutral formula. The CKD-EPI Creatinine Equation used for females: 142 x [min((Serum Creatinine)/0.7,1)] raised to the power of (-0.241) x max [((Serum Creatinine)/0.7,1) raised to the power of (-1.200)] x [0.9938] raised to the power of Age x 1.012. The CKD-EPI Creatinine Equation used for males: 142 x [min((Serum Creatinine)/0.9,1)] raised to the power of (-0.302) x max [((Serum Creatinine)/0.9,1) raised to the power of (-1.200)] x [0.9938] raised to the power of Age. The "index" serum creatinine is defined as the lowest serum creatinine value within the first 24 hours of encounter start. If there are no serum creatinine values within the first 24 hours, then the index is the first serum creatinine value within the first 48 hours of the encounter start. This serum creatinine value is used to identify and exclude patients with AKI at the start of the encounter. The "index" eGFR is calculated using the "index" serum creatinine, patient sex, and patient age based on the CKD-EPI Creatinine Equation. "Initiation" of kidney dialysis (CRRT, hemodialysis and peritoneal) during hospitalization is defined as documentation that kidney dialysis (CRRT, hemodialysis or peritoneal) was started during the encounter. In addition to clinical electronic health record data, this measure uses Present on Admission (POA) indicators (e.g., POA = U) as found in billing/claims system within the measure criteria. The POA Indicator is intended to differentiate conditions present at the time of admission from those conditions that develop during the inpatient admission. - A POA Indicator of Y = yes (Diagnosis was present at time of inpatient admission) - A POA Indicator of N = no (Diagnosis was not present at time of inpatient admission) - A POA Indicator of W = clinically undetermined - A POA Indicator of U = documentation insufficient to determine if the condition was present at the time of inpatient admission Per CMS and the Agency for Healthcare Research and Quality (AHRQ) convention, POA indicators of Y and W are accepted indicators of a diagnosis present on admission. POA indicators of N and U are accepted indicators of a diagnosis that is not present on admission. Show more >Inpatient hospitalizations: Includes time in the emergency department and observation when the transition between these encounters (if they exist) and the inpatient encounter are within an hour or less of each other. The numerator harm, AKI (stage 2 or greater), is defined as a substantial increase in serum creatinine value during the encounter, as evidenced by a subsequent increase in value at least 2 times higher than the lowest serum creatinine value, and the increased value is greater than the highest sex-specific normal value for serum creatinine. The following steps are performed to determine if this criterion for AKI is met: - To identify AKI, evaluate if any serum creatinine value obtained between 48 hours after the start of the encounter and either 30 days after the start of the encounter or discharge, whichever is sooner, is at least 1.5 times higher than the lowest value obtained within the prior 7 days. If yes, then: - Evaluate if the increased serum creatinine is greater than the highest sex-specific normal value for serum creatinine. If yes, then: - To stage AKI, evaluate if any serum creatinine value obtained between 48 hours after the start of the encounter and either 30 days after the start of the encounter or discharge, whichever is sooner, is at least 2 times higher than the lowest prior value (at any prior time) during that encounter. If yes, then: - Evaluate if the increased serum creatinine value is greater than the highest sex-specific normal value for serum creatinine. If yes, then a harm (AKI stage 2 or greater) has been identified. The highest normal serum creatinine value for females is defined as 1.02 mg/dL. The highest normal serum creatinine value for males is defined as 1.18 mg/dL. The eGFR values are calculated using the CKD-EPI Creatinine Equation, recommended by the National Kidney Foundation (Delgado et al., 2022). This is a sex-specific, race-neutral formula. The CKD-EPI Creatinine Equation used for females: 142 x [min((Serum Creatinine)/0.7,1)] raised to the power of (-0.241) x max [((Serum Creatinine)/0.7,1) raised to the power of (-1.200)] x [0.9938] raised to the power of Age x 1.012. The CKD-EPI Creatinine Equation used for males: 142 x [min((Serum Creatinine)/0.9,1)] raised to the power of (-0.302) x max [((Serum Creatinine)/0.9,1) raised to the power of (-1.200)] x [0.9938] raised to the power of Age. The "index" serum creatinine is defined as the lowest serum creatinine value within the first 24 hours of encounter start. If there are no serum creatinine values within the first 24 hours, then the index is the first serum creatinine value within the first 48 hours of the encounter start. This serum creatinine value is used to identify and exclude patients with AKI at the start of the encounter. The "index" eGFR is calculated using the "index" serum creatinine, patient sex, and patient age based on the CKD-EPI Creatinine Equation. "Initiation" of kidney dialysis (CRRT, hemodialysis and peritoneal) during hospitalization is defined as documentation that kidney dialysis (CRRT, hemodialysis or peritoneal) was started during the encounter. In addition to clinical electronic health record data, this measure uses Present on Admission (POA) indicators (e.g., POA = U) as found in billing/claims system within the measure criteria. The POA Indicator is intended to differentiate conditions present at the time of admission from those conditions that develop during the inpatient admission. - A POA Indicator of Y = yes (Diagnosis was present at time of inpatient admission) - A POA Indicator of N = no (Diagnosis was not present at time of inpatient admission) - A POA Indicator of W = clinically undetermined - A POA Indicator of U = documentation insufficient to determine if the condition was present at the time of inpatient admission Per CMS and the Agency for Healthcare Research and Quality (AHRQ) convention, POA indicators of Y and W are accepted indicators of a diagnosis present on admission. POA indicators of N and U are accepted indicators of a diagnosis that is not present on admission. Show less |
Inpatient hospitalizations: Includes time in the emergency department and observation when the transition between these encounters (if they exist) and the inpatient encounter are within an hour or less of each other. The numerator harm, AKI stage 2 or greater, is defined as an increase in...serum creatinine at least 2 times higher than the lowest serum creatinine value. The increased value must be greater than the highest sex-specific normal value for serum creatinine. The following steps are performed to determine if these criteria for AKI are met: - To identify AKI stage 2 or greater, evaluate if any serum creatinine value obtained between 48 hours after the start of the hospitalization and either discharge or 30 days after the start of the hospitalization, whichever is sooner, is at least 1.5 times higher than the lowest value obtained within the prior 7 days. If yes, then: - Evaluate if the increased serum creatinine is greater than the highest sex-specific normal value for serum creatinine. If yes, then: - To stage AKI, evaluate if any serum creatinine value obtained between 48 hours after the start of the hospitalization and either discharge or 30 days after the start of the hospitalization, whichever is sooner, is at least 2 times higher than the lowest prior value (at any prior time) during that encounter. If yes, then: - Evaluate if the increased serum creatinine value is greater than the highest sex-specific normal value for serum creatinine. If yes, then an AKI stage 2 or greater has been identified. The highest normal serum creatinine value for females is defined as 1.02 mg/dL. The highest normal serum creatinine value for males is defined as 1.18 mg/dL. The eGFR values are calculated using the CKD-EPI Creatinine Equation, recommended by the National Kidney Foundation (Delgado et al., 2022). This is a sex-specific, race-neutral formula. The CKD-EPI Creatinine Equation used for females: 142 x [min((Serum Creatinine)/0.7,1)] raised to the power of (-0.241) x max [((Serum Creatinine)/0.7,1) raised to the power of (-1.200)] x [0.9938] raised to the power of Age x 1.012. The CKD-EPI Creatinine Equation used for males: 142 x [min((Serum Creatinine)/0.9,1)] raised to the power of (-0.302) x max [((Serum Creatinine)/0.9,1) raised to the power of (-1.200)] x [0.9938] raised to the power of Age. The "index" serum creatinine is defined as the lowest serum creatinine value within the first 24 hours of encounter start. If there are no serum creatinine values within the first 24 hours, then the index is the first serum creatinine value within the first 48 hours of the encounter start. This serum creatinine value is used to identify and exclude patients with AKI at the start of the encounter. The "index" eGFR is calculated using the "index" serum creatinine, patient sex, and patient age based on the CKD-EPI Creatinine Equation. "Initiation" of kidney dialysis (CRRT, hemodialysis, and peritoneal) during hospitalization is defined as documentation that kidney dialysis (CRRT, hemodialysis, or peritoneal) was started during the encounter. In addition to clinical electronic health record data, this measure uses Present on Admission (POA) indicators (e.g., POA = U) as found in billing/claims system within the measure criteria. The POA Indicator is intended to differentiate conditions present at the time of admission from those conditions that develop during the inpatient admission. - A POA Indicator of Y = yes (Diagnosis was present at time of inpatient admission) - A POA Indicator of N = no (Diagnosis was not present at time of inpatient admission) - A POA Indicator of W = clinically undetermined - A POA Indicator of U = documentation insufficient to determine if the condition was present at the time of inpatient admission Per CMS and the Agency for Healthcare Research and Quality (AHRQ) convention, POA indicators of Y and W are accepted indicators of a diagnosis present on admission. POA indicators of N and U are accepted indicators of a diagnosis that is not present on admission. Show more >Inpatient hospitalizations: Includes time in the emergency department and observation when the transition between these encounters (if they exist) and the inpatient encounter are within an hour or less of each other. The numerator harm, AKI stage 2 or greater, is defined as an increase in serum creatinine at least 2 times higher than the lowest serum creatinine value. The increased value must be greater than the highest sex-specific normal value for serum creatinine. The following steps are performed to determine if these criteria for AKI are met: - To identify AKI stage 2 or greater, evaluate if any serum creatinine value obtained between 48 hours after the start of the hospitalization and either discharge or 30 days after the start of the hospitalization, whichever is sooner, is at least 1.5 times higher than the lowest value obtained within the prior 7 days. If yes, then: - Evaluate if the increased serum creatinine is greater than the highest sex-specific normal value for serum creatinine. If yes, then: - To stage AKI, evaluate if any serum creatinine value obtained between 48 hours after the start of the hospitalization and either discharge or 30 days after the start of the hospitalization, whichever is sooner, is at least 2 times higher than the lowest prior value (at any prior time) during that encounter. If yes, then: - Evaluate if the increased serum creatinine value is greater than the highest sex-specific normal value for serum creatinine. If yes, then an AKI stage 2 or greater has been identified. The highest normal serum creatinine value for females is defined as 1.02 mg/dL. The highest normal serum creatinine value for males is defined as 1.18 mg/dL. The eGFR values are calculated using the CKD-EPI Creatinine Equation, recommended by the National Kidney Foundation (Delgado et al., 2022). This is a sex-specific, race-neutral formula. The CKD-EPI Creatinine Equation used for females: 142 x [min((Serum Creatinine)/0.7,1)] raised to the power of (-0.241) x max [((Serum Creatinine)/0.7,1) raised to the power of (-1.200)] x [0.9938] raised to the power of Age x 1.012. The CKD-EPI Creatinine Equation used for males: 142 x [min((Serum Creatinine)/0.9,1)] raised to the power of (-0.302) x max [((Serum Creatinine)/0.9,1) raised to the power of (-1.200)] x [0.9938] raised to the power of Age. The "index" serum creatinine is defined as the lowest serum creatinine value within the first 24 hours of encounter start. If there are no serum creatinine values within the first 24 hours, then the index is the first serum creatinine value within the first 48 hours of the encounter start. This serum creatinine value is used to identify and exclude patients with AKI at the start of the encounter. The "index" eGFR is calculated using the "index" serum creatinine, patient sex, and patient age based on the CKD-EPI Creatinine Equation. "Initiation" of kidney dialysis (CRRT, hemodialysis, and peritoneal) during hospitalization is defined as documentation that kidney dialysis (CRRT, hemodialysis, or peritoneal) was started during the encounter. In addition to clinical electronic health record data, this measure uses Present on Admission (POA) indicators (e.g., POA = U) as found in billing/claims system within the measure criteria. The POA Indicator is intended to differentiate conditions present at the time of admission from those conditions that develop during the inpatient admission. - A POA Indicator of Y = yes (Diagnosis was present at time of inpatient admission) - A POA Indicator of N = no (Diagnosis was not present at time of inpatient admission) - A POA Indicator of W = clinically undetermined - A POA Indicator of U = documentation insufficient to determine if the condition was present at the time of inpatient admission Per CMS and the Agency for Healthcare Research and Quality (AHRQ) convention, POA indicators of Y and W are accepted indicators of a diagnosis present on admission. POA indicators of N and U are accepted indicators of a diagnosis that is not present on admission. Show less |
| Guidance | A patient characteristic of male or female sex is required as part of the initial population criteria, as sex is crucial to this measure. For example: - The eGFR estimating equation that is used to identify AKI is sex-specific; and- The reference ranges for the serum creatinine value are...sex-specific, which matters because the serum creatinine must rise to a sex-specific abnormal value to be flagged as AKI. Exclude encounters that do not have at least two serum creatine values within 48 hours of arrival. Two values are needed within this timeframe to determine if the patient has AKI or moderate-to-severe renal dysfunction on arrival. For encounters that show no patients with identified harm of 2.0 increase in serum creatinine, query for initiation of renal dialysis during hospitalization, defined by the start of dialysis occurring during the encounter. - If dialysis starts more than 48 hours after the start of the encounter, this meets numerator criteria. - If dialysis starts 48 hours or less after the start of the encounter, this meets denominator exclusion criteria. Encounters for patients with an increase in serum creatinine value of at least 0.3 mg/dL between the index serum creatinine and any subsequent serum creatinine taken within 48 hours of the encounter start are excluded. Due to the variability of decimal precision within programming languages and calculation tools, the value of >=0.3 is expressed in the logic as >0.299. Note the measure is currently confined to using mg/dL as the unit of measurement for creatinine and mL/min as the unit of measurement for eGFR results. When reporting the first body temperature for risk adjustment, values from either Celsius or Fahrenheit readings are acceptable to report but Celsius readings are preferred. Celsius readings conform to the Fast Healthcare Interoperability Resources (FHIR) standard which will assist with future FHIR implementations. This eCQM is an episode-based measure. An episode is defined as each inpatient hospitalization or encounter that ends during the measurement period. This version of the eCQM uses QDM version 5.6. Please refer to the QDM page for more information on the QDM. Show more >A patient characteristic of male or female sex is required as part of the initial population criteria, as sex is crucial to this measure. For example: - The eGFR estimating equation that is used to identify AKI is sex-specific; and - The reference ranges for the serum creatinine value are sex-specific, which matters because the serum creatinine must rise to a sex-specific abnormal value to be flagged as AKI. Exclude encounters that do not have at least two serum creatine values within 48 hours of arrival. Two values are needed within this timeframe to determine if the patient has AKI or moderate-to-severe renal dysfunction on arrival. For encounters that show no patients with identified harm of 2.0 increase in serum creatinine, query for initiation of renal dialysis during hospitalization, defined by the start of dialysis occurring during the encounter. - If dialysis starts more than 48 hours after the start of the encounter, this meets numerator criteria. - If dialysis starts 48 hours or less after the start of the encounter, this meets denominator exclusion criteria. Encounters for patients with an increase in serum creatinine value of at least 0.3 mg/dL between the index serum creatinine and any subsequent serum creatinine taken within 48 hours of the encounter start are excluded. Due to the variability of decimal precision within programming languages and calculation tools, the value of >=0.3 is expressed in the logic as >0.299. Note the measure is currently confined to using mg/dL as the unit of measurement for creatinine and mL/min as the unit of measurement for eGFR results. When reporting the first body temperature for risk adjustment, values from either Celsius or Fahrenheit readings are acceptable to report but Celsius readings are preferred. Celsius readings conform to the Fast Healthcare Interoperability Resources (FHIR) standard which will assist with future FHIR implementations. This eCQM is an episode-based measure. An episode is defined as each inpatient hospitalization or encounter that ends during the measurement period. This version of the eCQM uses QDM version 5.6. Please refer to the QDM page for more information on the QDM. Show less |
A patient characteristic of male or female sex is required as part of the initial population criteria, as sex is crucial to this measure. For example: - The eGFR estimating equation that is used to identify AKI is sex-specific; and- The reference ranges for the serum creatinine value are...sex-specific, which matters because the serum creatinine must rise to a sex-specific abnormal value to be flagged as AKI. Exclude encounters that do not have at least two serum creatine values within 48 hours of arrival. Two values are needed within this timeframe to determine if the patient has AKI or moderate-to-severe renal dysfunction on arrival. For encounters for patients without harm, as identified by 2 times increase in serum creatinine, query for initiation of renal dialysis during hospitalization, defined by the start of dialysis occurring during the encounter. - If dialysis starts more than 48 hours after the start of the encounter, this meets numerator criteria. - If dialysis starts 48 hours or less after the start of the encounter, this meets denominator exclusion criteria. Encounters for patients with an increase in serum creatinine value of at least 0.3 mg/dL between the index serum creatinine and any subsequent serum creatinine taken within 48 hours of the encounter start are excluded. Due to the variability of decimal precision within programming languages and calculation tools, the value of >=0.3 is expressed in the logic as >0.299. Note the measure is currently confined to using mg/dL as the unit of measurement for creatinine and mL/min as the unit of measurement for eGFR results. When reporting the first body temperature for risk adjustment, values from either Celsius or Fahrenheit readings are acceptable to report but Celsius readings are preferred. This eCQM is an episode-based measure. An episode is defined as each inpatient hospitalization or encounter that ends during the measurement period. This version of the eCQM uses QDM version 5.6. Please refer to the QDM page for more information on the QDM. Show more >A patient characteristic of male or female sex is required as part of the initial population criteria, as sex is crucial to this measure. For example: - The eGFR estimating equation that is used to identify AKI is sex-specific; and - The reference ranges for the serum creatinine value are sex-specific, which matters because the serum creatinine must rise to a sex-specific abnormal value to be flagged as AKI. Exclude encounters that do not have at least two serum creatine values within 48 hours of arrival. Two values are needed within this timeframe to determine if the patient has AKI or moderate-to-severe renal dysfunction on arrival. For encounters for patients without harm, as identified by 2 times increase in serum creatinine, query for initiation of renal dialysis during hospitalization, defined by the start of dialysis occurring during the encounter. - If dialysis starts more than 48 hours after the start of the encounter, this meets numerator criteria. - If dialysis starts 48 hours or less after the start of the encounter, this meets denominator exclusion criteria. Encounters for patients with an increase in serum creatinine value of at least 0.3 mg/dL between the index serum creatinine and any subsequent serum creatinine taken within 48 hours of the encounter start are excluded. Due to the variability of decimal precision within programming languages and calculation tools, the value of >=0.3 is expressed in the logic as >0.299. Note the measure is currently confined to using mg/dL as the unit of measurement for creatinine and mL/min as the unit of measurement for eGFR results. When reporting the first body temperature for risk adjustment, values from either Celsius or Fahrenheit readings are acceptable to report but Celsius readings are preferred. This eCQM is an episode-based measure. An episode is defined as each inpatient hospitalization or encounter that ends during the measurement period. This version of the eCQM uses QDM version 5.6. Please refer to the QDM page for more information on the QDM. Show less |
| Initial Population | Inpatient hospitalizations that end during the measurement period for patients 18 years of age or older without an obstetrical or pregnancy related condition, with a length of stay of 48 hours or longer, and who had at least one serum creatinine value after 48 hours from the start of the... hospitalization Show more >Inpatient hospitalizations that end during the measurement period for patients 18 years of age or older without an obstetrical or pregnancy related condition, with a length of stay of 48 hours or longer, and who had at least one serum creatinine value after 48 hours from the start of the hospitalization Show less |
Inpatient hospitalizations that end during the measurement period for patients 18 years of age or older without an obstetrical or pregnancy related condition, with a length of stay of 48 hours or longer, and who had at least one serum creatinine value after 48 hours from the start of the... hospitalization Show more >Inpatient hospitalizations that end during the measurement period for patients 18 years of age or older without an obstetrical or pregnancy related condition, with a length of stay of 48 hours or longer, and who had at least one serum creatinine value after 48 hours from the start of the hospitalization Show less |
| Denominator |
Equals Initial Population |
Equals Initial Population |
| Denominator Exclusions | Inpatient hospitalizations for patients with an increase in serum creatinine value of at least 0.3 mg/dL between the index serum creatinine and a subsequent serum creatinine taken within 48 hours of the encounter start.Inpatient hospitalizations for patients with the index eGFR value of...<60 mL/min within 48 hours of the encounter start. Inpatient hospitalizations for patients who have less than two serum creatinine results within the first 48 hours of the encounter start. Inpatient hospitalizations for patients who have kidney dialysis (CRRT, hemodialysis or peritoneal dialysis) initiated 48 hours or less after the encounter start, and who do not have evidence of a 2 times increase in serum creatinine. Inpatient hospitalizations for patients with at least one specified diagnosis present on admission during the encounter that puts them at extremely high risk for AKI: - Hemolytic Uremic Syndrome (HUS) - Large Body Surface Area (BSA) Burns - Traumatic Avulsion of Kidney - Rapidly Progressive Nephritic Syndrome - Thrombotic Thrombocytopenic Purpura - Out of Hospital Cardiac Arrest (OHCA) Inpatient hospitalizations for patients who have at least one specified procedure that starts during the encounter that puts them at extremely high risk for AKI: - Extracorporeal membrane oxygenation (ECMO) - Intra-Aortic Balloon Pump - Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) - Nephrectomy Show more >Inpatient hospitalizations for patients with an increase in serum creatinine value of at least 0.3 mg/dL between the index serum creatinine and a subsequent serum creatinine taken within 48 hours of the encounter start. Inpatient hospitalizations for patients with the index eGFR value of <60 mL/min within 48 hours of the encounter start. Inpatient hospitalizations for patients who have less than two serum creatinine results within the first 48 hours of the encounter start. Inpatient hospitalizations for patients who have kidney dialysis (CRRT, hemodialysis or peritoneal dialysis) initiated 48 hours or less after the encounter start, and who do not have evidence of a 2 times increase in serum creatinine. Inpatient hospitalizations for patients with at least one specified diagnosis present on admission during the encounter that puts them at extremely high risk for AKI: - Hemolytic Uremic Syndrome (HUS) - Large Body Surface Area (BSA) Burns - Traumatic Avulsion of Kidney - Rapidly Progressive Nephritic Syndrome - Thrombotic Thrombocytopenic Purpura - Out of Hospital Cardiac Arrest (OHCA) Inpatient hospitalizations for patients who have at least one specified procedure that starts during the encounter that puts them at extremely high risk for AKI: - Extracorporeal membrane oxygenation (ECMO) - Intra-Aortic Balloon Pump - Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) - Nephrectomy Show less |
Inpatient hospitalizations for patients with an increase in serum creatinine value of at least 0.3 mg/dL between the index serum creatinine and a subsequent serum creatinine taken within 48 hours of the encounter start. Inpatient hospitalizations for patients with the index eGFR value of...<60 mL/min within 48 hours of the encounter start. Inpatient hospitalizations for patients who have less than two serum creatinine results within the first 48 hours of the encounter start. Inpatient hospitalizations for patients who have kidney dialysis (CRRT, hemodialysis, or peritoneal dialysis) initiated 48 hours or less after the encounter start, and who do not have evidence of a 2 times increase in serum creatinine. Inpatient hospitalizations for patients with at least one specified diagnosis present on admission during the encounter that puts them at extremely high risk for AKI: - Hemolytic Uremic Syndrome (HUS) - Large Body Surface Area (BSA) Burns - Traumatic Avulsion of Kidney - Rapidly Progressive Nephritic Syndrome - Thrombotic Thrombocytopenic Purpura - Out of Hospital Cardiac Arrest (OHCA) Inpatient hospitalizations for patients who have at least one specified procedure that starts during the encounter that puts them at extremely high risk for AKI: - Extracorporeal membrane oxygenation (ECMO) - Intra-Aortic Balloon Pump - Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) - Nephrectomy Show more >Inpatient hospitalizations for patients with an increase in serum creatinine value of at least 0.3 mg/dL between the index serum creatinine and a subsequent serum creatinine taken within 48 hours of the encounter start. Inpatient hospitalizations for patients with the index eGFR value of <60 mL/min within 48 hours of the encounter start. Inpatient hospitalizations for patients who have less than two serum creatinine results within the first 48 hours of the encounter start. Inpatient hospitalizations for patients who have kidney dialysis (CRRT, hemodialysis, or peritoneal dialysis) initiated 48 hours or less after the encounter start, and who do not have evidence of a 2 times increase in serum creatinine. Inpatient hospitalizations for patients with at least one specified diagnosis present on admission during the encounter that puts them at extremely high risk for AKI: - Hemolytic Uremic Syndrome (HUS) - Large Body Surface Area (BSA) Burns - Traumatic Avulsion of Kidney - Rapidly Progressive Nephritic Syndrome - Thrombotic Thrombocytopenic Purpura - Out of Hospital Cardiac Arrest (OHCA) Inpatient hospitalizations for patients who have at least one specified procedure that starts during the encounter that puts them at extremely high risk for AKI: - Extracorporeal membrane oxygenation (ECMO) - Intra-Aortic Balloon Pump - Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) - Nephrectomy Show less |
| Numerator | Inpatient hospitalizations for patients who develop AKI (stage 2 or greater) during the encounter, as evidenced by: A subsequent increase in serum creatinine value at least 2 times higher than the lowest serum creatinine value, and the increased value is greater than the highest...sex-specific normal value for serum creatinine. Or: Kidney dialysis (CRRT, hemodialysis or peritoneal dialysis) initiated more than 48 hours after the start of the encounter. Evidence of a 2 times increase in serum creatinine is not required. Only one harm is counted per encounter. Show more >Inpatient hospitalizations for patients who develop AKI (stage 2 or greater) during the encounter, as evidenced by: A subsequent increase in serum creatinine value at least 2 times higher than the lowest serum creatinine value, and the increased value is greater than the highest sex-specific normal value for serum creatinine. Or: Kidney dialysis (CRRT, hemodialysis or peritoneal dialysis) initiated more than 48 hours after the start of the encounter. Evidence of a 2 times increase in serum creatinine is not required. Only one harm is counted per encounter. Show less |
Inpatient hospitalizations for patients who develop AKI stage 2 or greater during the encounter, as evidenced by: A subsequent increase in serum creatinine value at least 2 times higher than the lowest serum creatinine value, and the increased value is greater than the highest...sex-specific normal value for serum creatinine. Or: Kidney dialysis (CRRT, hemodialysis, or peritoneal dialysis) initiated more than 48 hours after the start of the encounter. Evidence of a 2 times increase in serum creatinine is not required. Only one harm is counted per encounter. Show more >Inpatient hospitalizations for patients who develop AKI stage 2 or greater during the encounter, as evidenced by: A subsequent increase in serum creatinine value at least 2 times higher than the lowest serum creatinine value, and the increased value is greater than the highest sex-specific normal value for serum creatinine. Or: Kidney dialysis (CRRT, hemodialysis, or peritoneal dialysis) initiated more than 48 hours after the start of the encounter. Evidence of a 2 times increase in serum creatinine is not required. Only one harm is counted per encounter. Show less |
| Numerator Exclusions |
Not Applicable |
None |
| Denominator Exceptions |
None |
None |
| Next Version | No Version Available | |
| Previous Version | No Version Available |
- This is a risk adjusted measure; Risk Adjustment Methodology Report: Acute Kidney Injury's Risk Adjustment Methodology Report (Updated June 20, 2023)
- There is a known issue on CMS832v2. See issue EKI-35 on the ONC eCQM Known Issues Dashboard for details.
Additional Resources for CMS832v2
*Note there may be more tickets for CMS832v2 in the eCQM Tracker - ASTP/ONC Project Tracking System (Jira). Only tickets tagged with their associated CMS measure ID appear.
Use the eCQM Tracker to open new issues regarding eCQM implementation. Log in required.
Header
Updated the eCQM version number.
Measure Section:
eCQM Version Number
Source of Change:
Annual Update
Changed all references from NQF to CBE to identify the consensus-based entity role.
Measure Section:
CBE Number
Source of Change:
Annual Update
Updated copyright.
Measure Section:
Copyright
Source of Change:
Annual Update
Updated disclaimer.
Measure Section:
Disclaimer
Source of Change:
Annual Update
Added a statement in the guidance that a patient characteristic of male or female sex is required as part of the initial population criteria, as sex-specific calculations are crucial to the measure.
Measure Section:
Guidance
Source of Change:
Measure Lead
Added guidance that temperature values from Celsius readings are preferred over those from Fahrenheit readings to assist with future Fast Healthcare Interoperability Resources (FHIR) implementations.
Measure Section:
Guidance
Source of Change:
Measure Lead
Added a denominator exclusion for inpatient hospitalizations for patients with a diagnosis of acute cardiac arrest present on admission due to clinical reasons.
Measure Section:
Denominator Exclusions
Source of Change:
Measure Lead
Updated grammar, wording, and/or formatting to improve readability and consistency.
Measure Section:
Multiple Sections
Source of Change:
Measure Lead
Updated references and measure header to reflect current evidence and new or updated literature.
Measure Section:
Multiple Sections
Source of Change:
Measure Lead
Logic
Revised the Initial Population to require a patient characteristic of male or female sex.
Measure Section:
Initial Population
Source of Change:
Measure Lead
Removed redundant timing logic from the 'Inpatient Encounter with Creatinine' definition.
Measure Section:
Definitions
Source of Change:
Measure Lead
Renamed value set to 'Payer Type' to more accurately reflect the contents and intent of the value set.
Measure Section:
Definitions
Source of Change:
Standards/Technical Update
Updated the names of CQL definitions, functions, and/or aliases for clarification and to align with the CQL Style Guide.
Measure Section:
Definitions
Source of Change:
Standards/Technical Update
Updated the version number of the Measure Authoring Tool (MAT) Global Common Functions Library to v8.0.000 and the library name from 'MATGlobalCommonFunctions' to 'MATGlobalCommonFunctionsQDM.'
Measure Section:
Definitions
Source of Change:
Annual Update
Updated the version number of the Measure Authoring Tool (MAT) Global Common Functions Library to v8.0.000 and the library name from 'MATGlobalCommonFunctions' to 'MATGlobalCommonFunctionsQDM.'
Measure Section:
Functions
Source of Change:
Annual Update
Value Set
The VSAC is the source of truth for the value set content, please visit the VSAC for downloads of current value sets.
Value set (2.16.840.1.113762.1.4.1045.152): Renamed to Body Temperature based on recommended value set naming conventions.
Measure Section:
Terminology
Source of Change:
Annual Update
Value set High Risk Diagnosis for AKI (2.16.840.1.113762.1.4.1248.12): Added 3 ICD-10-CM codes (I46.2, I46.8, I46.9) based on change in measure requirements/measure specification.
Measure Section:
Terminology
Source of Change:
Measure Lead
Value set High Risk Procedures for AKI (2.16.840.1.113762.1.4.1248.19): Added 2 SNOMED CT codes (108022006, 265550007) based on review by technical experts, SMEs, and/or public feedback.
Measure Section:
Terminology
Source of Change:
Measure Lead
Value set Hospital Based Dialysis Services (2.16.840.1.113762.1.4.1248.199): Added 1 SNOMED CT code (341939001) based on review by technical experts, SMEs, and/or public feedback. Added 1 SNOMED CT code (48781000175105) based on terminology update.
Measure Section:
Terminology
Source of Change:
Measure Lead
Value set (2.16.840.1.114222.4.11.3591): Renamed to Payer Type based on recommended value set naming conventions.
Measure Section:
Terminology
Source of Change:
Annual Update
Replaced value set Obstetrics and VTE Obstetrics (2.16.840.1.113762.1.4.1248.33) with value set Obstetrical or Pregnancy Related Conditions (2.16.840.1.113883.3.117.1.7.1.263) based on review by technical experts, SMEs, and/or public feedback.
Measure Section:
Terminology
Source of Change:
Measure Lead